Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Report 2026

Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Overview

• Hereditary Breast and Ovarian Cancer Syndrome Treatment market size has reached to $7.07 billion in 2025 • Expected to grow to $9.69 billion in 2030 at a compound annual growth rate (CAGR) of 6.7% • Growth Driver: Rising Prevalence Of Ovarian Cancer Drives Growth In The Hereditary Breast And Ovarian Cancer Syndrome Treatment Market • Market Trend: Innovative Treatment Approaches In The Hereditary Breast And Ovarian Cancer Syndrome Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?

The hereditary breast and ovarian cancer syndrome (HBO) treatment refers to the collective measures and medical approaches taken to address the elevated risk of developing breast and ovarian cancers in individuals with a genetic predisposition to the syndrome. Hereditary breast and ovarian cancer syndrome (HBO) treatment can help to prevent cancer from developing or detecting it early when it is more treatable. The main hereditary breast and ovarian cancer syndrome treatments are hormonal therapy, chemoprevention, genetic counselling, medication, and others. Hormone replacement therapy should be transient and estrogen-based and targeted toward individual acute symptoms for hereditary breast and ovarian cancer (HBOC) syndrome particularly for those with BRCA1 or BRCA2 mutations. It is diagnosed by genetic testing, magnetic resonance imaging (MRI), mammography, and others. The medication can be administered through oral, parenteral, and other routes by hospitals, specialty clinics, homecare, and others.

What Is The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Growth Forecast?

The hereditary breast and ovarian cancer syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $9.69 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to expansion of personalized oncology treatment approaches, increasing adoption of preventive surgeries, growth in targeted and immunotherapy development, rising investments in genetic diagnostics, improved long-term patient monitoring solutions. Major trends in the forecast period include increasing adoption of genetic counselling services, rising use of preventive therapeutic strategies, growing integration of targeted cancer therapies, expansion of risk-based screening programs, enhanced focus on early intervention approaches.

Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Segmentation

1) By Treatment: Hormonal Therapy, Chemoprevention, Genetic Counselling, Medication, Other Treatments 2) By Diagnosis: Genetic Testing, Magnetic Resonance Imaging (MRI), Mammography, Other Diagnosis 3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments: 1) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors 2) By Chemoprevention: Tamoxifen, Raloxifene 3) By Genetic Counselling: Risk Assessment, Family Planning Guidance 4) By Medication: Targeted Therapies, Immune Checkpoint Inhibitors 5) By Other Treatments: Preventive Surgery, Surveillance Strategies

What Is The Driver Of The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?

The rise in the prevalence of ovarian cancer is expected to propel the growth of the hereditary breast and ovarian cancer syndrome treatment market going forward. Ovarian cancer is a malignant tumor that develops in the ovaries, the female reproductive organs responsible for producing eggs and hormones. This shift has resulted from increased longevity, delayed childbearing, and lifestyle changes. Hereditary Breast and Ovarian Cancer Syndrome (HBOC) is a genetic condition that increases the rate of developing breast, ovarian, and other cancers. For instance, in April 2024, according to the World Ovarian Cancer Coalition, a Canada-based not-for-profit organization, in 2022, approximately 324,603 women worldwide were diagnosed with ovarian cancer. By 2050, the annual number of cases is projected to approach half a million, reflecting a 55% increase. Therefore, the rising prevalence of ovarian cancer is driving the growth of hereditary breast and ovarian cancer syndrome treatment industry.

Key Players In The Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co., AbbVie Inc., Bayer AG, Sanofi-Aventis LLC, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Seagen Inc., Genentech Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Myriad Genetics Inc., Invitae Corporation, Natera Inc., LifeLabs Genetics, Abbott Laboratories

Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Trends and Insights

Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market are adopting new treatment options, such as comprehensive risk tests, to provide reliable services to the customers. A complete risk assessment test is a tool that helps to identify an individual's risk of developing a disorder or experiencing a symptom of a disease. For instance, in February 2023, Genetic Technologies Limited, an Australia-based molecular diagnostics company, launched a ground-breaking comprehensive risk assessment test, a type of treatment for breast and ovarian cancer. It combines gene mutation testing for breast and ovarian cancers, hereditary and non-hereditary risk factors, and the GeneType risk score for both cancers. It has a unique approach that combines the detection of the 13 primary actionable breast and ovarian cancer susceptibility genes with the GeneType test platform. The new test platform addresses women over 30 who, outside of unusual genetic alterations, are at higher risk of developing breast and ovarian cancer in the general population.

What Are Latest Mergers And Acquisitions In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?

In March 2023, Invitae Corporation, a US-based biotechnology company, partnered with Epic Systems Corporation. This partnership aims to streamline the genetic testing procedure, incorporate genetic information into standard workflows, and enhance customized healthcare delivery within the Epic community. Epic Systems Corporation is a US-based platform provider to aid in assessing a patient's risk for hereditary cancer, including hereditary breast and ovarian cancer syndrome (HBOC).

Regional Outlook

North America was the largest region in the hereditary breast and ovarian cancer syndrome treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?

The hereditary breast and ovarian cancer syndrome treatment market consists of revenues earned by entities by providing services such as genetic testing and counseling, surveillance, screening, prophylactic surgeries, chemoprevention, clinical trials, ongoing monitoring, family testing, and psychosocial support. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary breast and ovarian cancer syndrome treatment market also includes sales of lynparza, talazoparib, rucaparib, and niraparib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Report 2026?

The hereditary breast and ovarian cancer syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary breast and ovarian cancer syndrome treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.